Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Sep 25;2(10):1160-1167.
doi: 10.1002/hep4.1247. eCollection 2018 Oct.

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis

Nathan Ford  1 , Roz Scourse  2 , Maud Lemoine  3 , Yvan Hutin  1 , Marc Bulterys  1 , Zara Shubber  4 , Dmytro Donchuk  5 , Gilles Wandeler  6
Affiliations
Review

Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis

Nathan Ford et al. Hepatol Commun. .

Abstract

Successful treatment outcomes for chronic hepatitis B virus (HBV) infection requires high levels of adherence to treatment. We searched three databases and abstracts from two conferences up to January 2018 for studies reporting the proportion of patients who were adherent to HBV antiviral therapy and pooled data using random effects meta-analysis. We included 30 studies, providing data for 23,823 patients. Overall, adherence to treatment was 74.6% (95% confidence interval [CI] 67.1%-82.1%). Adherence was similar in high-income settings (75.1%; 95% CI, 65.4%-85.0%) and in low-income and middle-income settings (72.9%; 95% CI, 57.8%-88.0%). Reported barriers to adherence included forgetting, limited understanding of the importance of adherence, and change to routine. Conclusion : There is a need to reinforce assessment and reporting of adherence as a routine part of HBV care and to assess the extent to which evidence-based interventions to improve adherence to medication for human immunodeficiency virus [HIV] and other chronic diseases are effective for HBV infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection process. Abbreviations: ART, antiretroviral therapy; IFN, interferon.
Figure 2
Figure 2
Pooled proportion of patients adherent to HBV medication. Data points represent percentage adherence and 95% CI. Diamonds represent pooled proportions. Dotted line indicates the overall pooled proportion.
See this image and copyright information in PMC

References

    1. World Health Organization . Global Hepatitis Report. Geneva, Switzerland: World Health Organization; 2017.
    1. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, et al. C‐TEAM study group and the Taiwan Liver Diseases Consortium. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int 2016;36:1755‐1764. - PubMed
    1. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology 2017;66:1444‐1453. - PubMed
    1. Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment outcomes with first‐line therapies with entecavir and tenofovir in treatment‐naive chronic hepatitis B patients in a routine clinical practice. J Clin Gastroenterol 2016;50:169‐174. - PubMed
    1. Chotiyaputta W, Hongthanakorn C, Oberhelman K, Fontana RJ, Licari T, Lok AS. Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs. J Viral Hepat 2012;19:205‐212. - PubMed